Skip to main content

Advertisement

SpringerLink
Log in

Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association

  • Hypertension and the Kidney (RM Carey, Section Editor)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi. Chronic kidney disease (CKD) and hypertension (HTN) are two major public health problems, and both are associated with increased risk of cardiovascular events. Emerging evidence suggests a pathogenic role of hyperuricemia in the development of HTN and CKD, in addition to progression of CKD, by inducing renal inflammation, endothelial dysfunction, and activation of the renin-angiotensin system. In addition, several epidemiological studies have linked hyperuricemia with an increased risk of HTN and CKD. A few clinical trials have assessed the use of uric acid-lowering therapies such as allopurinol and febuxostat in the management of HTN and delaying progression of CKD. To date, most of these trials are short-term with a small sample size; however, their results are encouraging and provide a rationale for larger randomized controlled trials to establish the role of uric acid-lowering therapies in the management of HTN, in addition to prevention of CKD progression and cardiovascular events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rock KL, Kataoka H, Lai JJ. Uric acid as a danger signal in gout and its comorbidities. Nat Rev Rheumatol. 2013;9(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  2. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr. 2012;4:12.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8 Suppl 1:S1.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kanbay M et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 2016;29:3–8.

    Article  CAS  PubMed  Google Scholar 

  5. Mende C. Management of chronic kidney disease: the relationship between serum uric acid and development of nephropathy. Adv Ther. 2015;32(12):1177–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Couser WG et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011;80(12):1258–70.

    Article  PubMed  Google Scholar 

  7. Mallat SG, Itani HS, Tanios BY. Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control. 2013;6:69–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jalal DI et al. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–46.

    Article  CAS  PubMed  Google Scholar 

  9. Maiuolo J et al. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8–14.

    Article  PubMed  Google Scholar 

  10. Moriwaki Y. Effects on uric acid metabolism of the drugs except the antihyperuricemics. J Bioequivalence Bioavailab. 2014;2014.

  11. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis. 2012;19(6):358–71.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lioté F. Hyperuricemia and gout. Curr Rheumatol Rep. 2003;5(3):227–34.

    Article  PubMed  Google Scholar 

  13. McDonagh EM et al. PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics. Pharmacogenet Genomics. 2014;24(9):464–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Terkeltaub R. Update on gout: new therapeutic strategies and options.

  15. Li L et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lapi F et al. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zhu, J., et al., Dietary factors associated with hyperuricemia and glyeolipid metabolism disorder in middle-aged and elderly people. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2016. 47(1): p. 68.

  18. Guan S et al. Prevalence of hyperuricemia among Beijing post-menopausal women in 10 years. Arch Gerontol Geriatr. 2016;64:162–6.

    Article  CAS  PubMed  Google Scholar 

  19. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007–2008. Arthritis Rheum. 2011;63(10):3136–41.

    Article  PubMed  Google Scholar 

  20. Anton FM et al. Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (E2) on the renal handling of urate. Metabolism. 1986;35(4):343–8.

    Article  CAS  PubMed  Google Scholar 

  21. Liu B, et al. The prevalence of hyperuricemia in China: a meta-analysis. BMC Public Health. 2011;11(1):1–10.

  22. Hak AE, Choi HK. Menopause, postmenopausal hormone use and serum uric acid levels in US women—the third national health and nutrition examination survey. Arthritis Res Ther. 2008;10(5):R116.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Grayson PC et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res. 2011;63(1):102–10.

    Article  CAS  Google Scholar 

  24. Cicero AF et al. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella heart study. J Hypertens. 2014;32(1):57–64.

    Article  CAS  PubMed  Google Scholar 

  25. Perlstein TS et al. Uric acid and the development of hypertension: the normative aging study. Hypertension. 2006;48(6):1031–6.

    Article  CAS  PubMed  Google Scholar 

  26. Yu M-A et al. Oxidative stress with an activation of the renin–angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 2010;28:1234–42.

    PubMed  Google Scholar 

  27. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;5(38):1101–6.

    Article  Google Scholar 

  28. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148–56.

    Article  CAS  PubMed  Google Scholar 

  29. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Kanbay M et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–33.

    Article  CAS  PubMed  Google Scholar 

  31. Isaka Y, et al. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol Dial Transplant. 2015.

  32. Weiner DE et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Uchida S et al. Targeting uric acid and the inhibition of progression to end-stage renal disease—a propensity score analysis. PLoS One. 2015;10(12):e0145506.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Shi Y et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2011;35(3):153–60.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Miao Y et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58(1):2–7.

    Article  CAS  PubMed  Google Scholar 

  36. Wanner C et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–34.

    Article  PubMed  Google Scholar 

  37. Siu YP et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–9.

    Article  CAS  PubMed  Google Scholar 

  38. Goicoechea M et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sircar D et al. Efficacy of febuxostat for slowing the GFR Decline in patients With CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–50.

    Article  CAS  PubMed  Google Scholar 

  40. Mancia G, Grassi G, Borghi C. Hyperuricemia, urate deposition and the association with hypertension. Curr Med Res Opin. 2015;31 Suppl 2:15–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Nephrology, American University of Beirut, Beirut, Lebanon

    Samir G. Mallat & Bassem Y. Tanios

  2. Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Riad-El-Solh, 1107 2020, Beirut, Lebanon

    Sahar Al Kattar & Abdo Jurjus

Authors
  1. Samir G. Mallat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sahar Al Kattar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bassem Y. Tanios
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdo Jurjus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abdo Jurjus.

Ethics declarations

Conflict of Interest

Drs. Mallat, Al Kattar, Tanios, and Jurjus declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Hypertension and the Kidney

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mallat, S.G., Al Kattar, S., Tanios, B.Y. et al. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. Curr Hypertens Rep 18, 74 (2016). https://doi.org/10.1007/s11906-016-0684-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11906-016-0684-z

Keywords

Search

Navigation